KRAS and lung carcinoma: Also in lung cancer, oncogenic KRAS allows for irreversible MYC overexpression, thereby driving cytosolic phospholipase A2 activity to release membrane-bound arachidonic acid and activate lipoxygenase and cyclooxygenase pathways (62).